---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073509"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:59:25.001036+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MannKind Q4 revenue $112M (+46% YoY); Furoscix adds $23M in first quarter

## Summary
- Total revenues $112M in Q4 2025, up 46% vs Q4 2024; full-year revenues $349M, up 22%.
- Afrezza net sales $23M in Q4, +25% YoY; Furoscix net sales $23M since acquisition Oct 7, 2025.
- PDUFA target dates: Afrezza pediatric sBLA May 29, 2026; Furoscix ReadyFlow sNDA July 26, 2026.
- R&D expense $27.6M (+148% YoY); SG&A $58.4M (+144%) driven by Furoscix and launch prep.
- Cash & investments $176M at Dec 31, 2025; scPharmaceuticals acquisition completed Oct 7.

## SEC filing metadata
- accession: 0001193125-26-073509
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/0001193125-26-073509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073509
- JSON: https://secwatch.observer/filing/0001193125-26-073509.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073509.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.